RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 17, 2019, by Relmada Therapeutics, Inc. (RLMD), a Nevada corporation. The report addresses the filing of Amendment No. 2 to its Registration Statement on Form S-1 (Registration No. 333-233228) and the retroactive adjustment of financial statements to reflect a 1-for-4 reverse stock split completed on September 30, 2019.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references the attachment of audited consolidated financial statements for the fiscal years ended June 30, 2019, and 2018, which have been adjusted to reflect the reverse split. The filing confirms the existence of these statements but does not summarize the specific figures within the text of the 8-K.
Material Changes
- Reverse Stock Split: The company completed a 1-for-4 reverse split of its common stock on September 30, 2019.
- Financial Statement Adjustments: All share and per-share numbers in the audited financial statements and Management's Discussion and Analysis (MD&A) for the fiscal years ended June 30, 2019, and 2018, have been adjusted retroactively to give effect to the reverse split.
- Registration Statement Update: Amendment No. 2 to the Form S-1 was filed to incorporate these adjusted financial items.
Guidance, Outlook, and Risks
The filing does not contain new management guidance, outlook, or specific risk factors beyond the procedural update regarding the reverse split and the filing of amended financial documents. The report states there are no changes to the information filed on October 17, 2019, other than the retroactive adjustments for the stock split.
Investor Verification Checklist
- Verify the adjusted share count and per-share metrics in the attached Exhibit 99.1 (Audited Financial Statements) and Exhibit 99.2 (MD&A).
- Confirm the impact of the 1-for-4 reverse split on the company's liquidity and market capitalization.
- Review the full text of Amendment No. 2 to Form S-1 (Registration No. 333-233228) for details on the proposed offering.
- Check the status of the company's compliance with NASDAQ listing requirements following the reverse split.